Apr 9 |
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
|
Feb 28 |
COGT Reports Full Year 2023 Financial Results and Business Highlights
|
Feb 26 |
Cogent downgraded at Baird on rare disease drug data
|
Feb 26 |
Cogent Biosciences GAAP EPS of -$0.63
|
Feb 26 |
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
|
Feb 22 |
Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib
|
Feb 22 |
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
|
Feb 14 |
Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
|
Feb 14 |
Cogent Biosciences announces oversubscribed $225M private placement
|
Feb 14 |
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
|